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Prognostic Value of Plasma Fibrinolysis
Activation Markers in Cardiovascular Disease
Diana A. Gorog, MD, PHD
London, United Kingdom
The pivotal role of hypoactive endogenous fibrinolysis in the occurrence of thrombotic cardiovascular events is
now well-recognized. To evaluate the diagnostic and prognostic role of impaired fibrinolysis, plasma fibrinolysis
markers have been investigated in large prospective studies in both healthy individuals and patients with estab-
lished coronary disease. Antigen and activity levels of components of the fibrinolytic system were measured by
immunoassays, which replaced earlier global fibrinolysis tests. This review covers 45 studies in nearly 50,000
subjects, examining the association between plasma markers of fibrinolysis and coronary artery disease, to es-
tablish the usefulness of these markers in predicting future cardiovascular events. The predictive value of
plasma levels of tissue-type plasminogen activator, platelet activator inhibitor-1, plasmin-antiplasmin complex,
D-dimer, thrombin activatable fibrinolysis inhibitor, and lipoprotein(a) for major adverse cardiac events is highly
variable and conflicting, especially after adjusting for conventional risk factors, judging from the published data
in the last decade. The value of fibrinolysis activity markers is very limited in aiding diagnosis and risk stratifica-
tion in the individual patient, on the basis of the weak prognostic values obtained in some studies and the lack
of power in others. The physiological limitations of such markers in reflecting endogenous fibrinolysis is dis-
cussed. The emerging novel global assays of fibrinolysis will require large-scale clinical trials before their prog-
nostic power or superiority to multiple biomarker measurements can be evaluated. (J Am Coll Cardiol 2010;
55:2701–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.095w
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dcope of This Review
he measurement of plasma markers of fibrinolysis dates
ack more than 20 years. This review covers the last 10
ears, from 1999 to July 2009. Earlier findings were re-
iewed by Lijnen and Collen (1) and Hoffmeister et al. (2).
new review is timely, because a number of new fibrinolysis
arkers have been discovered and a large number of clinical
tudies have been carried out with improved, more sensitive
mmunoassays.
This review covers 45 prospective studies in nearly 50,000
ubjects, examining the association between plasma markers
f fibrinolysis and coronary artery disease (CAD), to estab-
ish the usefulness of these markers in predicting future
ardiovascular events. Of the prospective studies, only those
hat have evaluated the results by multivariate regression
nalysis and calculated relative risk are shown in Table 1.
ignificance of Endogenous Fibrinolysis
n Acute Coronary Syndromes (ACS)
ndogenous fibrinolysis is a protective mechanism against
asting arterial thrombotic occlusion, which would other-
rom the Imperial College, London, United Kingdom.s
Manuscript received September 14, 2009; revised manuscript received October 26,
009, accepted November 2, 2009.ise lead to permanent tissue damage. Because arterial
hrombogenesis is an active, ongoing, and dynamic process,
healthy endogenous fibrinolytic system can prevent the
uild-up of thrombus before complete occlusion occurs or
reak up the occlusive thrombus before lasting tissue dam-
ge ensues.
Until the early 1980s, coronary artery spasm and dimin-
shed myocardial oxygen supply were regarded as the fun-
amental mechanisms of myocardial infarction (3,4). Cor-
nary artery thrombosis as the major pathogenic mechanism
f sudden death from ischemic heart disease was disputed
ainly because autopsy studies reported a very low incidence of
dentifiable coronary thrombus. By performing early autopsies,
ith improved techniques, the British pathologist Dr. Michael
avies first reported coronary thrombi in 74 of 100 subjects
ho died of ischemic heart disease and, of all these, only 5
ubjects had no acute arterial lesion (5). Similar findings were
eported by others, showing that the infarct-related artery was
ccluded in 90% of cases within the first 6 h of acute
yocardial infarction (AMI), whereas this fell to 57% by 12 to
4 h (6). Growing evidence from cases of spontaneous lysis of
rterial thrombi further supported the pathology findings and
rovided an explanation for the failure of earlier studies to
etect thrombi at late autopsies (7–10).
Over the last decade, increasing evidence has emerged toupport the assumption that AMI is a failure of timely
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Fibrinolysis Markers in Cardiovascular Disease June 15, 2010:2701–9spontaneous thrombolysis (11).
Spontaneous reperfusion of the
infarct-related artery was re-
ported to occur frequently in pa-
tients with AMI and was associ-
ated with significant myocardial
salvage (12). In 585 patients with
ST-segment elevation myocardial
infarction (STEMI), electrocar-
diographic or angiographic spon-
taneous reperfusion (SR) was ob-
served in 15%, and those with SR
had lower mortality, lower com-
posite of death/shock/congestive
heart failure, and significant reduc-
tion in death or reinfarction (13).
In a recent study of 710 patients
with STEMI undergoing primary
percutaneous coronary interven-
tion (PCI), SR was observed in
22% of patients and at 30 days was
associated with significantly lower
incidence of death, congestive
heart failure, and recurrent ACS
(14). It has been suggested that
impaired fibrinolysis at the time
of coronary angioplasty contrib-
utes to restenosis (15). Deficient
local endothelial tissue-type plas-
minogen activator (TPA) release
in patients with CAD indicates
reduced local fibrinolytic capacity
and might explain the increased
risk of coronary thrombosis in
this patient group (16). Recently,
ow plasma fibrinolytic potential, found in 10% of the
opulation, was found to increase the relative risk of arterial
hrombosis 2-fold (17).
ssessment of Overall
ibrinolytic Status by Biomarkers
he mechanism and elements of the fibrinolytic system
ave been reviewed recently, and are shown in simplified
chematic in Figure 1 (18,19). Thrombin converts the
nactive proenzyme plasminogen to active plasmin. Plasmin
egrades the cross-linked fibrin into soluble degradation
roducts by the tissue-type (TPA) and the urokinase type
lasminogen activators. It is TPA that is mainly responsible
or the dissolution of fibrin formed in the circulation. This
brinolytic system can be inhibited either by antagonizing
lasmin through alpha 2-antiplasmin or by specific plasmin-
gen activator inhibitors (PAI). There are 3 types of PAI
escribed so far; of these, physiologically the most impor-
ant inhibitor is PAI type 1 (PAI-1). The thrombin acti-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
CAD  coronary artery
disease
ELISA  enzyme-linked
immunoadsorbent assay
HR  hazard ratio
Lp(a)  lipoprotein(a)
MACE  major adverse
cardiovascular event
OR  odds ratio
PAI  plasminogen
activator inhibitor
PAP  plasmin-alpha2-
antiplasmin complex
PCI  percutaneous
coronary intervention
SR  spontaneous
reperfusion
STEMI  ST-segment
elevation myocardial
infarction
TAFI  thrombin
activatable fibrinolysis
inhibitor
TAFI-Ag  thrombin
activatable fibrinolysis
inhibitor antigen
TPA  tissue-type
plasminogen activatoratable fibrinolysis inhibitor (TAFI) is another important St
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June 15, 2010:2701–9 Fibrinolysis Markers in Cardiovascular Diseasenhibitor of the fibrinolytic system. The TAFI forms a link
etween blood coagulation and fibrinolysis. Thrombin
orms fibrin to stabilize the platelet-rich thrombus and at
he same time produces TAFI to protect that fibrin net-
ork. The TAFI circulates as an inactive proenzyme in
lood and becomes activated by thrombin during blood
lotting. The active form (TAFIa) inhibits fibrinolysis by
leaving off C-terminal lysine residues from partially de-
raded fibrin that stimulate the TPA-mediated conversion
f plasminogen to plasmin. Consequently, removal of these
ysines leads to less plasmin formation and subsequently to
rotection of the fibrin clot from breakdown.
Although the plasmin-mediated fibrinolytic system is the
ajor physiological mechanism of removing fibrin from the
irculation, the plasmin-independent breakdown of fibrin
y cellular components of blood also plays a significant role.
n arterial thrombus contains significant amounts of leu-
ocytes (neutrophils and monocytes) covering the thrombus
urface or incorporated into it, due to interaction of acti-
ated platelets with leukocytes. Neutrophil membrane pro-
eolytic enzymes (elastase, cathepsin G) can break down
brin directly and can assist the dissolution of thrombus by
lasmin (20). Furthermore, the physical properties of fibrin
ormed during hemostasis/thrombosis greatly affect the rate
nd effectiveness of fibrinolysis. Clots formed from blood of
CS patients are composed of dense networks of fibrin that
re more resistant to lysis than clots derived from patients
ith stable angina (21).
In the past decade, clinical studies on endogenous fibri-
olysis have investigated the following biomarkers: alpha2-
ntiplasmin-plasmin complex; alpha-2 antiplasmin, TPA,
arkers of fibrin turnover, such as fibrin degradation
roducts, D-dimer, and soluble fibrin. Discovery of TAFI
nd the finding that plasma lipoprotein(a) [Lp(a)], a homo-
ogue of plasminogen, can inhibit TPA-mediated plasmin-
Figure 1 Schematic Diagram Showing Overview of the Fibrinoly
1Tissue-type plasminogen activator. 2Plasminogen activator inhibitor-1, the primary
nolysis inhibitor attenuates fibrinolysis by inhibiting plasmin formation. 4Because o
vation on fibrin surfaces. 5D-dimer is a fibrin degradation product released when p
proteolytic enzyme plasmin that digests fibrin. ()  activator; (–)  inhibitor.gen activation on fibrin surfaces have attracted much ottention, and the contribution of these 2 physiologically
mportant fibrinolysis inhibitors to overall fibrinolytic status
as also been investigated in patients with CAD.
PA and PAI-1
aradoxically, increased plasma TPA indicates inhibited
ndogenous fibrinolysis. This is because free TPA released
nto blood from endothelial cells immediately forms a
omplex with circulating PAI-1. Thus assays of TPA
ntigen measure mainly inactive TPA/PAI-1 complexes.
oncentration of the TPA/PAI-1 complex levels in plasma
orrelated strongly with levels of TPA antigen and PAI-1
ctivity (22,23).
There is evidence that TPA levels predict cardiovascular
isease in apparently healthy individuals. In a prospective
tudy of 3,582 women ages 60 to 70 years, there was a
ositive but weak association (hazard ratio [HR]: 1.2)
etween TPA and the development of CAD (24). In a
ested case-control study of CAD patients and healthy
ndividuals, TPA was an independent risk factor for the
volution of coronary disease (25). Elevated TPA antigen
as independently associated with incident coronary events
odds ratio [OR]: 3.5) in post-menopausal women (26).
Furthermore, TPA levels predict future cardiovascular
vents in patients with established CAD. In stable angina
atients (27) and in a number of studies involving AMI
atients, including the MIRACL (Myocardial Ischemia
eduction with Aggressive Cholesterol Lowering) study of
,860 patients, raised TPA level was related to greatly
ncreased risk of recurrent events (28–30).
The PAI-1 levels have also been related to adverse
ardiovascular outcomes in both healthy individuals and
ardiac patients. The Caerphilly Study of 2,398 middle-
ged men followed-up for 13 years found that baseline levels
athway
ological inhibitor of plasminogen activation in blood. 3Thrombin-activatable fibri-
omology with plasminogen, lipoprotein(a) inhibits TPA-mediated plasminogen acti-
degrades the crosslinked fibrin. 6Alpha2-antiplasmin is the major inhibitor of thetic P
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Fibrinolysis Markers in Cardiovascular Disease June 15, 2010:2701–9ccurrence of a cardiovascular event (31). A prospective
tudy of 249 angina patients found that those with higher
AI-1 activity (especially diabetic patients) had a 4.2-fold
isk of subsequent coronary events (32). In 180 AMI
atients, raised levels of PAI-1 on admission were associ-
ted with greatly increased risk of cardiogenic shock and
n-hospital and 1-year mortality (OR: 6.0) (33). In 520
atients with ACS, increased PAI-1 was a significant and
ndependent risk factor for the occurrence of major adverse
ardiovascular events (MACE) (OR: 5.3) (34). A recent
ase control study found that the 4G4G genotype of the
G/5G PAI-1 gene polymorphism was more frequently
bserved in patients with prior AMI than those with stable
oronary disease and was an independent predictor of AMI
OR: 2.7, p  0.002) (35).
Similarly, levels of TPA/PAI-1 complex also predict
uture events. In the SHEEP (Stockholm Heart Epidemi-
logy Program) study of some 800 AMI patients and
atched control subjects, high levels of TPA/PAI-1 com-
lex were significantly associated with AMI risk, with a
ynergistic interaction observed in men for the co-exposure
o high plasma TPA/PAI-1 complex concentrations and
moking, diabetes mellitus, and serum cholesterol (36).
However, there have also been negative studies. In the
,209 participants of the Framingham study, PAI-1 levels
ere not related to cardiovascular events (37). In the
DVANCE (Action in Diabetes and Vascular Disease:
reterax and Diamicron Modified Release [MR] Con-
rolled Evaluation) study, plasma TPA and PAI-1 levels did
ot distinguish patients presenting with AMI from those
ith stable angina (38). Furthermore, 2 small prospective
tudies in AMI patients followed for 3 years, which also did
ot identify a prognostic role for baseline TPA or PAI-1
evels in predicting future cardiovascular events (39,40).
-Dimer
here are mixed data on the predictive value of plasma
-dimer level in healthy individuals. In large, prospective
tudies of elderly subjects, D-dimer level has been shown to
redict future AMI (OR: 2.5) (41) and cardiovascular death
OR: 4.0) (42). In the Caerphilly Study, where 2,398
iddle-aged men were followed-up for 13 years, D-dimer
evel was associated with future cardiovascular events (31).
n post-menopausal women, D-dimer was independently
ssociated with the occurrence of coronary events (OR: 2.0)
26). In contrast, in 3,209 participants in the Framingham
tudy, plasma D-dimer was not predictive of MACE (37).
nother large prospective study of 3,582 women ages 60 to
0 years found no association between D-dimer and devel-
pment of CAD (24). In the Multiethnic Study of Athero-
clerosis, raised D-dimer levels were related to increased risk
f death but not nonfatal cardiovascular events in more than
,000 subjects (43).
In patients with established CAD, data are again con-
icting. In the MIRACL study of 2,860 patients with ACS t28) as well as 2 other smaller studies in ACS (39,44),
-dimer levels were not predictive of subsequent cardiovas-
ular events. However, in AMI patients undergoing primary
CI (n 102), baseline D-dimer was significantly higher in
atients who developed subsequent restenosis (61%) than
hose who did not (25%) (45). Furthermore, in patients with
ecompensated heart failure, D-dimer levels were signifi-
ant predictors of mortality (46).
The specificity of D-dimer for cardiovascular disease is
uestionable. In 257 patients with chest pain, raised
-dimer had an independent diagnostic value for AMI
positive and negative predictive values estimated as 92%
nd 41%, respectively) and increased the diagnostic sensi-
ivity of the electrocardiogram and history from 73% to 92%
47). In another study of 279 patients with suspected ACS,
-dimer showed significantly higher positive test rate for
he detection of ACS in the very early phase compared with
roponin T and therefore was regarded useful for the
creening of ACS in the emergency setting (48). In the
DVANCE Study, however, D-dimer did not distinguish
atients presenting with AMI from those with stable angina
38). In large prospective studies investigating a multima-
ker approach to the initial assessment of patients with chest
ain, D-dimer did not aid detection of ACS or predict
rognosis above and beyond established risk factors (49,50).
AP
here are conflicting data on the value of plasmin-alpha2-
ntiplasmin complex (PAP) measurement. In the Cardio-
ascular Health Study of 5,201 healthy men and women
ges 65 years, PAP level predicted future AMI (OR: 3.1)
41). In 200 AMI patients, low plasma PAP level was
ssociated with subsequent coronary events (OR: 5.0) (51).
n the large Multiethnic Study of Atherosclerosis (n 
,391), PAP was associated with increased risk of death
HR: 2.00) but not with nonfatal cardiovascular events (43).
n contrast, however, in the AtheroGene study of 1,057
AD patients, PAP was not predictive of subsequent
ardiovascular death (52), and in a small study of patients
ndergoing elective PCI, PAP failed to differentiate be-
ween patients with and those without restenosis (53).
AFI
igh TAFI plasma levels might contribute to a hypofi-
rinolytic state and to an increased risk of thrombotic
pisodes.
Some studies reported low thrombin activatable fibrino-
ysis inhibitor antigen (TAFI-Ag) levels in patients with
AD and attributed a cardio-protective role to reduced
AFI levels against MACE, contrary to expectation. In a
ase-control study of some 600 AMI patients, TAFI-Ag
alue above the 90th percentile was associated with a
ignificantly lower risk of AMI (OR: 0.55) (54). Similarly,
n the case-control SMILE (Study of Myocardial Infarc-
ions Leiden) of 554 men with a first AMI, low activated
T
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June 15, 2010:2701–9 Fibrinolysis Markers in Cardiovascular DiseaseAFI levels were associated with increased risk of AMI
OR: 2.4 to 3.4) (55). The ATTAC (Role of Thrombin
ctivatable Fibrinolysis Inhibitor in Arterial Thrombosis at
Young Age) study identified the TAFI 325Thr/Ile poly-
orphism to be associated with lower TAFI levels and with
ncreased risk of cardiovascular disease in young patients
ompared with the common 325Thr/Thr genotype (56).
olymorphism of the TAFI gene (Thr325lle) was not only
elated to TAFI-Ag plasma levels but also to angiographic
estenosis after PCI (57).
However, other studies have found CAD associated with
aised TAFI levels. The AtheroGene Study in 1,668 pa-
ients with angiographically proven CAD showed that
ncrease of activated TAFI, measured by TAFIa/TAFIai
nzyme-linked immunoadsorbent assay (ELISA), but not
f the total amount of TAFI to be independently associated
ith risk of cardiovascular death (HR: 1.7) (58). The TAFI
evels also tended to be higher in CAD patients as compared
ith control subjects, especially in intracoronary blood
amples (59). Furthermore, TAFI-Ag levels were found to
e lower but functional activated TAFI levels were signifi-
antly higher in young patients with AMI than in control
ubjects (60). In patients with stable angina undergoing
CI, pre-procedural plasma TAFI-Ag levels were signifi-
antly higher in those who developed restenosis (61).
There were other studies that were neutral. The TAFI
evels were not associated with an increased risk of arterial
hrombosis in thrombophilic families (n  1,940) (62). In
4 patients admitted to the coronary care unit and compared
ith 44 control subjects, no differences were found in either
AFI-Ag or activated TAFI between patients and control
ubjects (63).
p(a)
arly studies reported only a weak association of Lp(a) with
hrombotic risk. In 520 ACS patients, Lp(a) was not a risk
actor for future MACE (34). The larger PROSPER
prospective study of pravastatin in the elderly at risk) Study
roup, where entry Lp(a) levels were measured in 5,732
lderly subjects who were followed for 3.2 years, found a
eak association between Lp(a) and risk of cardiovascular
vents (HR: 1.1, p  0.032) (64).
Subsequent studies have found plasma Lp(a) levels to be
onsistently predictive of arterial thrombotic occlusion. In
44 patients with STEMI undergoing early coronary an-
iography (12 h), baseline Lp(a) levels were inversely
elated to infarct-related artery patency, with highest Lp(a)
evels associated with angiographic TIMI flow grade 0 to 1
OR: 3.1) (65). In patients with premature coronary disease
n  142), plasma Lp(a) levels were significantly higher
han in control subjects (39). In the THROMBO (Throm-
ogenic Factors and Recurrent Coronary Events) study of
bese post-infarction patients (n 663), elevated Lp(a) was
highly significant risk marker of recurrent cardiovascular
vents (HR: 3.94) (66). In 876 subjects undergoing screen- Cng for vascular disease prevention, Lp(a) levels were
trongly associated with the presence of silent carotid
cclusion (OR: 1.7; p  0.0001) (67).
However, the association between plasma Lp(a) levels
nd burden of coronary atheroma is less well-established. In
97 patients undergoing coronary angiography, Lp(a) was
ignificantly associated with the presence and severity of
oronary stenosis (OR: 1.2) (68). In 397 patients undergo-
ng coronary angiography, high Lp(a) levels were indepen-
ently associated with the presence of coronary obstruction
OR: 2.5) (69). Yet, in patients undergoing PCI with
ngiographic follow-up, plasma Lp(a) concentrations were
ot predictive of restenosis (70).
Recently the first meta-analysis of long-term prospec-
ive studies investigating Lp(a) published over the last 40
ears, involving nearly 127,000 subjects, was reported.
nder a wide range of circumstances, there were inde-
endent and modest associations of Lp(a) concentration
ith risk of coronary disease (HR: 1.13, 95% confidence
nterval: 1.1 to 1.2) and stroke that seem exclusive to
ascular outcomes (71).
A recent study found only the oxidized Lp(a) to be
ssociated with presence and severity of ACS and suggested
hat oxidized Lp(a) plasma level measurement could be
seful for identification of patients with ACS (72).
Despite the growing interest in the predictive power of
his fibrinolysis marker, existing methodological problems
till prevent the use of Lp(a) as a routine diagnostic tool
73). However, existing evidence shows that Lp(a) levels are
elated to cardiovascular risk, which is mediated through
hrombosis and impaired fibrinolysis.
rognostic and Diagnostic Value
f Fibrinolysis Markers
he overall outcome of these studies for all measured
arkers is highly controversial. Even without allowing for
ublication bias, the number of negative studies unable to
emonstrate an association or predictive power is practically
qual to those reporting a positive association and prognos-
ic value. Even some of the so-called “positive” studies
eport relative risks that, although significant, are so weak
HR: 1.1 to 1.7) that they indicate only a statistical trend
ut have little practical usefulness. Conflicting findings of
ither low or high TAFI levels being associated with
ardiovascular risk might be related to the discrepancy
etween measurements of total TAFI-Ag or TAFI activity,
ither in all patients or in only those with specific TAFI
enotypes. Furthermore, methodological problems curtail
he use of Lp(a) in routine clinical practice.
The limitations of these biomarkers (see the following
ext) might provide an explanation for the conflicting results
nd for the failure of large-scale studies of fibrinolysis
arkers to reflect the true endogenous fibrinolytic status in
AD patients.
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. Do not reflect leukocyte-mediated fibrinolysis; neutrophil
lastase interferes with D-dimer and PAI-1 measurements.
s mentioned earlier, leukocyte-derived enzymes, mainly
lastase, released from thrombus-associated neutrophils,
ffect fibrinolysis by direct digestion of fibrin or indirectly
odulate it by degradation inhibitors of the fibrinolytic
ystem. Neutrophil elastase degrades fibrin and also de-
rades D-dimer and inactivates PAI-1 (74). Although the
leavage and inactivation of PAI-1 by neutrophil elastase
nhances fibrinolysis, degradation reduces plasma D-dimer
oncentration and might be partly responsible for discrepant
esults when comparing different D-dimer assays. Fibrino-
en elastase degradation products might serve as a specific
arker of elastase proteolytic activity. In a case-control
tudy, significantly higher fibrinogen elastase degradation
roduct levels were observed in patients with ischemic
troke than in control subjects, both in the acute and in the
onvalescent phase (75).
. Plasma PAI-1/TAFI measurements do not reflect
ndogenous thrombolytic capacity. The main limitation
f plasma PAI-1 measurement is that it does not reflect the
ocal release of PAI-1 from activated platelets during
hrombogenesis. Platelets contain approximately 90% of the
otal amount of PAI-1 present in blood (76). During
hrombus formation, thrombin is generated by activated
latelets resulting in the release of functionally active PAI-1
rom platelet granules. The resultant high local concentra-
ion of PAI-1 in the thrombus mass prevents thrombolysis.
t has been shown that the plasma and the platelet pools of
AI-1 vary independently of each other in disease states
77). Platelet-derived PAI-1 concentration was much
igher than plasma PAI-1 on day 1 after AMI, and
learance rates of plasma and platelet PAI-1 from the
ystemic circulation were different (78). Thus, measurement
f plasma PAI-1 level bears very little relation to the true
ontribution of PAI-1 (mainly from platelet release) to the
tability of an arterial thrombus. That PAI-1 is predomi-
antly platelet derived, is demonstrated by a recent report
hat clopidogrel pre-treatment completely abolishes the
ncrease in PAI-1 active antigen after coronary stenting
79). Peri-procedural platelet activation might play a major
ole in the increase in PAI-1 after PCI, increasing the risk
f acute and subacute thrombus formation not only through
latelet activation but also due to impairment of the
ndogenous fibrinolytic system. By inhibiting platelet
2Y(12) receptors, which are involved in thrombin gener-
tion, clopidogrel inhibits thrombin-induced release of
AI-1 from platelets.
In addition to PAI-1 release, TAFI activation is also
ssociated with thrombogenesis. The TAFI is activated
hrough proteolytic cleavage by thrombin. Thrombin does
ot form in the systemic circulation but is generated by
ctivated platelets during thrombus formation. Thrombin
ot only plays a central role in thrombogenesis by forming pfibrin network that confers structural stability to the labile
latelet aggregate but is also involved in stabilizing the
ormed thrombus by activating TAFI. Activated TAFI
rotects the fibrin-stabilized thrombus against lysis (80).
ecent findings show that thrombus-adherent monocytes
nhibit fibrinolysis through a tissue factor-mediated en-
ancement of TAFI activation and increase the resistance of
he thrombus to fibrinolysis (81). Because both thrombin
eneration and TAFI activation are highly localized pro-
esses in the thrombus, plasma TAFI level measurements
ear little relevance to the actual thrombolytic status.
. Measurements of total antigen, specific activities, or gene
olymorphism of fibrinolysis markers yield conflicting
linical results. It is still not clear whether total antigen or
ctivity measurements better reflect the physiological situa-
ion. Both quantitative and qualitative differences exist
etween studies measuring either the total antigen levels by
he standard commercial ELISA methods and those report-
ng biological activities by immunofunctional chromogenic
ubstrate kinetic assays. In plasma from patients with
oronary disease, no statistical difference in PAI-1 activity,
AI-1 antigen, or PAI-1/TPA complex was observed
ompared with normal subjects (82). Because of the rela-
ively long plasma half-life of PAI-1 activity (approximately
h), antigen and activity measurements might go hand in
and in healthy subjects. However, the poor correlation
etween measurements of TAFI-Ag and activity might be
ecause activated TAFI is quickly inactivated by a rapid
pontaneous conversion to the latent form with a half-life of
pproximately 10 min (83). Therefore, the very short
alf-life of TAFIa presents a practical measurement prob-
em, which is difficult to overcome in clinical settings (84).
his might explain why 1 study found that only the plasma
evel of activated TAFI, measured by TAFIa/TAFIai
LISA but not the total amount of TAFI was indepen-
ently associated with risk of cardiovascular death (56,58).
Because background plasma PAI-1 and TAFI concentra-
ions are almost entirely genetically determined, the contro-
ersial clinical findings might be explained by gene varia-
ions, including polymorphisms in the PAI-1 and TAFI
enes. Compared with the commonest haplotype of the
AI-1 gene G-5G-A-A-T (35.1%), the haplotype A-4G-
-A-C (32.7%) significantly increased the risk of coronary
isease and showed significant associations with common
isk factors (85,86). By contrast, a randomized study found
o impact of the PAI-1 4G/5G polymorphism on the
mount of myocardial salvage achieved by reperfusion with
tenting or thrombolysis in patients with AMI (87). More-
ver, although the 4G allele was associated with higher
AI-1 levels, there was no association of the PAI-1 gene
olymorphism with the risk of AMI (88,89).
. Do not reflect hypofibrinolysis caused by altered fibrin
rchitecture and the effects of drugs on fibrin network
orosity. Physical properties of fibrin are major determi-
ants of the efficacy of endogenous fibrinolysis. Abnormal
lasma fibrin architecture seems to be an important feature
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urvivors and impacts on fibrinolysis rate (90). Aspirin
ncreases fibrinolysis, as demonstrated by shortened fibrin
lot “lysis time” in parallel with an increase in fibrin network
orosity (91). The effects of such altered fibrin architecture
nd drugs are not reflected in current biomarker assays.
iomarkers or Global Assays of Fibrinolysis?
ven before the development of molecular markers and
heir immunoassays, global spontaneous fibrinolysis of hu-
an plasma had been measured. However, spontaneous
brinolysis of plasma clots is an extremely slow process. In
he quantification of clot lysis with the release of 125I from
abeled fibrin, lysis was 10% or less at 20 h (92). Laboratory
ssays of global fibrinolysis such as the fibrin plate method
nd euglobulin clot lysis time greatly contributed to the
nderstanding of the molecular mechanism of the fibrino-
ytic system but had little place in clinical practice, because
hey were labor-intensive and time-consuming. Recognition
f the limitations of biomarkers in assessing global fibrino-
ytic status stimulated development of new global tests. The
lobal thrombosis test measures the lysis of an autologous
latelet-rich thrombus, formed from native blood exposed
o high shear stress (93). The clot formation and lysis assay
s an automated microtiter plate spectrophotometric assay of
lot formation and lysis due to added TPA (94). The global
ssay of overall hemostasis potential measures clot-lysis by
dded rTPA, expressing the results as fibrinolysis profile
95). The fibrinolysis parameters assay is a rapid global assay
or plasma fibrinolysis, whereas cellular fibrinolysis is mea-
ured by testing the clot-lysis capacity with polymorphonu-
lear neutrophils (96). The intrinsic oxidative clot lysis assay
ses chloramines as the source of singlet oxygen to enhance
rokinase type plasminogen activator-mediated lysis of
lasma clots (97). The global fibrinolytic capacity of
hole blood samples represents a global assessment of the
ain fibrinolytic factors in plasma and those associated
ith blood cells (98). The clot lysis time assay measures
brinolytic activity by the lysis time of a tissue factor-
nduced clot (99).
This review shows that, despite improved specificity and
efinement of factorial assays, the predictive value of fibri-
olysis markers for coronary events is disappointing. This is
t least in part due to the uncertainty about what to measure
antigens, activity, or genetic polymorphism in key proteins
f the fibrinolytic system) as well as the inherent limitation
f using a simple factorial assessment to quantify the
omplex and dynamic process of fibrinolysis. On a practical
evel, such individual markers fail to provide the rapid,
eaningful, and individualized assessment of fibrinolytic
tatus that is needed. From a clinical perspective, what is
eeded is a simple, global, point-of-care test that reflects not
nly overall plasma fibrinolytic capacity but also other
eterminants of endogenous thrombolytic activity, such as
he contribution of platelets and the physical properties ofhe formed fibrin. The value of such global tests of fibrino-
ysis in the clinical setting and their superiority over the
actorial approach with biomarkers remains to be estab-
ished with well-conducted prospective studies.
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